Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02734251 · ClinicalTrials.gov registry record · NA
Effect of Relora Supplement on Anxiety, Cognitive Performance & Mood Tested After Induced Stress
A NA study of Mood (Psychological Function), sponsored by InterHealth Nutraceuticals.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT02734251: Completed NA study of Mood (Psychological Function), sponsored by InterHealth Nutraceuticals.
NCT02734251 is a NA study of Mood (Psychological Function) that has completed, run by InterHealth Nutraceuticals. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02734251, a NA study of Mood (Psychological Function), has completed, sponsored by InterHealth Nutraceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The present randomized, double-blind, placebo-controlled crossover trial aims to evaluate the effects of Relora supplementation on responses to induced stress produced by a combination of cognitive and physiologic stressors in healthy men and women. The effects of the supplement, compared with a placebo, will be evaluated using measures to assess anxiety \[State-Trait Anxiety Inventory-Part 1 (STAI-Part 1), mood \[Bond-Lader Visual Analog Scale (VAS)\], hypothalamic-pituitary-adrenal axis activation (salivary cortisol) and cognitive function (cognitive flexibility, reaction time, processing speed, attention, sustained attention, working memory, and executive function). Testing will be completed at the beginning and end of 7-d supplementation periods with the active and placebo products to assess both the acute effects and the "acute-on-chronic" effects following one week of daily use.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Relora
Study Locations (1)
Florida
- MB Clinical Research - Boca Raton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-02 |
| Phase | NA |
What the finished NCT02734251 record still lists
NCT02734251 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Mood (Psychological Function) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02734251 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02734251 about?
NCT02734251 is a clinical study titled "Effect of Relora Supplement on Anxiety, Cognitive Performance & Mood Tested After Induced Stress". The present randomized, double-blind, placebo-controlled crossover trial aims to evaluate the effects of Relora supplementation on responses to induced stress produced by a combination of cognitive and physiologic stressors in healthy men and women. The effects of the supplement, compared with a pla...
What is the current status of trial NCT02734251?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2016-02.
What conditions does trial NCT02734251 study?
This clinical trial studies the following conditions: Mood (Psychological Function).
What interventions are being tested in trial NCT02734251?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Relora (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02734251?
This trial is sponsored by InterHealth Nutraceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02734251 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02734251's enrollment target sits among peer trials
36 1541st of 2000 higher than 437 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia